Physician profile
Long Ly
NPI 1023638871
$3,301.47
in general payments reported to CMS, 2019-2025
20 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,666 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,117.48 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.28 | 2024-2025 | |
| Janssen Biotech, INC. | $468.42 | 2024-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $370.90 | 2025 | |
| Janssen Scientific Affairs, LLC | $273.18 | 2024 | Tremfya |
| Galderma Laboratories, L.P. | $252.30 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $193.91 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $183.85 | 2025 | Jublia, Siliq, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $167.60 | 2024-2025 | Dupixent |
| Ucb, INC. | $143.17 | 2024-2025 | Bimzelx |
| Regeneron Pharmaceuticals, INC. | $117.91 | 2024-2025 | Dupixent |
| Fresenius Kabi USA, LLC | $117.85 | 2024 | Idacio |
| Lilly USA, LLC | $108.28 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $73.99 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $70.26 | 2025 | |
| Sun Pharmaceutical Industries INC. | $58.26 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $47.94 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.06 | 2024-2025 | Spevigo |
| Pfizer INC. | $38.06 | 2024-2025 | |
| Dermavant Sciences, INC. | $22.53 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $18.72 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.